Week in Review: Hepalink Pharma Buys US-based CMO Cytovance

Shenzhen Hepalink Pharma will acquire Cytovance, a US biologics CMO, for $205 million; Shanghai Pharma will launch a $470 million China VC fund for China healthcare startups with partners; DynoSense, a San Jose medical device company, closed a $9.4 million Series A from China-US investors; Jiangxi Boya Bio-Pharma will acquire stakes in two China pharmas; Harbin Gloria Pharma plans to buy a 70% interest in Sheyang Zhenyang Hospital for $27.5 million; Cellular Research, a Silicon Valley genetics company supported by China's Decheng Capital, was acquired by BD Life Sciences; Shanghai Kehua Bio-Engineering signed an MOU to acquire Technogenetics of Italy in a diagnostics tie-up; ECM Medical, a US-China medical device company, acquired China rights to a novel spinal fusion device from Vertebral of Minnesota; Lee's Pharm acquired China rights to two single-dose infusion products from San Francisco-based BioQuiddity; Eddingpharm in-licensed greater China rights to a second CV drug from Canada's Cardiome; and the CFDA is developing a pilot plan to approve INDs for oncology drugs in 60 days. More details.... Stock Symbols: (SHZ: 002399) (SHA: 600196) (SHZ: 300294) (SHZ: 002437) (SHZ: 2022) (HK: 0950) (NSDQ: CRME; TSX: COM) Share this with colleagues: // //